» Articles » PMID: 33951044

Genotype-phenotype Correlation in Neurofibromatosis Type-1: NF1 Whole Gene Deletions Lead to High Tumor-burden and Increased Tumor-growth

Overview
Journal PLoS Genet
Specialty Genetics
Date 2021 May 5
PMID 33951044
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Neurofibromatosis type-1 (NF1) patients suffer from cutaneous and subcutaneous neurofibromas (CNF) and large plexiform neurofibromas (PNF). Whole gene deletions of the NF1 gene can cause a more severe phenotype compared to smaller intragenic changes. Two distinct groups of NF1 whole gene deletions are type-1 deletions and atypical deletions. Our aim was to assess volumes and averaged annual growth-rates of CNF and PNF in patients with NF1 whole gene deletions and to compare these with NF1 patients without large deletions of the NF1 gene. We retrospectively evaluated 140 whole-body MR examinations of 38 patients with NF1 whole gene deletions (type-1 group: n = 27/atypical group n = 11) and an age- and sex matched collective of 38 NF1-patients. Age-dependent subgroups were created (0-18 vs >18 years). Sixty-four patients received follow-up MRI examinations (NF1whole gene deletion n = 32/control group n = 32). Whole-body tumor-volumes were semi-automatically assessed (MedX, V3.42). Tumor volumes and averaged annual growth-rates were compared. Median tumor-burden was significantly higher in the type-1 group (418ml; IQR 77 - 950ml, p = 0.012) but not in the atypical group (356ml;IQR 140-1190ml, p = 0.099) when compared to the controls (49ml; IQR 11-691ml). Averaged annual growth rates were significantly higher in both the type-1 group (14%/year; IQR 45-36%/year, p = 0.004) and atypical group (11%/year; IQR 5-23%/year, p = 0.014) compared to the controls (4%/year; IQR1-8%/year). Averaged annual growth rates were significantly higher in pediatric patients with type-1 deletions (21%/year) compared with adult patients (8%/year, p = 0.014) and also compared with pediatric patients without large deletions of the NF1 gene (3.3%/year, p = 0.0015). NF1 whole gene deletions cause a more severe phenotype of NF1 with higher tumor burden and higher growth-rates compared to NF1 patients without large deletions of the NF1 gene. In particular, pediatric patients with type-1 deletions display a pronounced tumor growth.

Citing Articles

Increased Phenotype Severity Associated with Splice-Site Variants in a Hungarian Pediatric Neurofibromatosis 1 Cohort: A Retrospective Study.

Veres K, Nagy B, Ember Z, Bene J, Hadzsiev K, Medvecz M Biomedicines. 2025; 13(1).

PMID: 39857730 PMC: 11762399. DOI: 10.3390/biomedicines13010146.


SUCLG1 promotes aerobic respiration and progression in plexiform neurofibroma.

Zhou Z, Li Q, Huo R Int J Oncol. 2025; 66(2.

PMID: 39749698 PMC: 11753773. DOI: 10.3892/ijo.2024.5716.


Visual Deficits and Diagnostic and Therapeutic Strategies for Neurofibromatosis Type 1: Bridging Science and Patient-Centered Care.

Miyagishima K, Qiao F, Stasheff S, Nadal-Nicolas F Vision (Basel). 2024; 8(2).

PMID: 38804352 PMC: 11130890. DOI: 10.3390/vision8020031.


Study on the value of multi-dimensional conformal radiotherapy and functional imaging in tumor bioimaging.

Huang D, He L, Xiong M, Sun Q Transl Cancer Res. 2022; 11(10):3780-3789.

PMID: 36388020 PMC: 9641124. DOI: 10.21037/tcr-22-2005.


Evaluation of magnetic resonance imaging-based radiomics characteristics for differentiation of benign and malignant peripheral nerve sheath tumors in neurofibromatosis type 1.

Ristow I, Madesta F, Well L, Shenas F, Wright F, Molwitz I Neuro Oncol. 2022; 24(10):1790-1798.

PMID: 35426432 PMC: 9527508. DOI: 10.1093/neuonc/noac100.


References
1.
Kehrer-Sawatzki H, Mautner V, Cooper D . Emerging genotype-phenotype relationships in patients with large NF1 deletions. Hum Genet. 2017; 136(4):349-376. PMC: 5370280. DOI: 10.1007/s00439-017-1766-y. View

2.
Kluwe L, Nguyen R, Vogt J, Bengesser K, Mussotter T, Friedrich R . Internal tumor burden in neurofibromatosis Type I patients with large NF1 deletions. Genes Chromosomes Cancer. 2012; 51(5):447-51. DOI: 10.1002/gcc.21931. View

3.
Uusitalo E, Rantanen M, Kallionpaa R, Poyhonen M, Leppavirta J, Yla-Outinen H . Distinctive Cancer Associations in Patients With Neurofibromatosis Type 1. J Clin Oncol. 2016; 34(17):1978-86. DOI: 10.1200/JCO.2015.65.3576. View

4.
Rasmussen S, Colman S, Ho V, Abernathy C, Arn P, WEISS L . Constitutional and mosaic large NF1 gene deletions in neurofibromatosis type 1. J Med Genet. 1998; 35(6):468-71. PMC: 1051340. DOI: 10.1136/jmg.35.6.468. View

5.
Zheng H, Chang L, Patel N, Yang J, Lowe L, Burns D . Induction of abnormal proliferation by nonmyelinating schwann cells triggers neurofibroma formation. Cancer Cell. 2008; 13(2):117-28. DOI: 10.1016/j.ccr.2008.01.002. View